- Home
- SCNI vs GRI Comparison
SCNI vs GRI Comparison
Compare SCNI & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- GRI
- Stock Information
- Founded
- SCNI 2003
- GRI 2018
- Country
- SCNI Israel
- GRI United States
- Employees
- SCNI N/A
- GRI N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- GRI Health Care
- Exchange
- SCNI Nasdaq
- GRI Nasdaq
- Market Cap
- SCNI 3.5M
- GRI 3.0M
- IPO Year
- SCNI N/A
- GRI N/A
- Fundamental
- Price
- SCNI $2.84
- GRI $0.77
- Analyst Decision
- SCNI
- GRI Strong Buy
- Analyst Count
- SCNI 0
- GRI 1
- Target Price
- SCNI N/A
- GRI $12.00
- AVG Volume (30 Days)
- SCNI 12.9K
- GRI 9.9M
- Earning Date
- SCNI 11-29-2024
- GRI 11-14-2024
- Dividend Yield
- SCNI N/A
- GRI N/A
- EPS Growth
- SCNI N/A
- GRI N/A
- EPS
- SCNI N/A
- GRI N/A
- Revenue
- SCNI $284,000.00
- GRI N/A
- Revenue This Year
- SCNI N/A
- GRI N/A
- Revenue Next Year
- SCNI N/A
- GRI N/A
- P/E Ratio
- SCNI N/A
- GRI N/A
- Revenue Growth
- SCNI N/A
- GRI N/A
- 52 Week Low
- SCNI $2.23
- GRI $0.30
- 52 Week High
- SCNI $8.92
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- SCNI 30.31
- GRI 49.32
- Support Level
- SCNI $2.91
- GRI $0.79
- Resistance Level
- SCNI $3.70
- GRI $1.00
- Average True Range (ATR)
- SCNI 0.21
- GRI 0.17
- MACD
- SCNI -0.07
- GRI -0.02
- Stochastic Oscillator
- SCNI 7.37
- GRI 24.95
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.